VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

PRESS RELEASE

Amsterdam, The Netherlands, 19 January 2023

Annogen to develop multiple CNS-cell specific promoters for VectorY programs

VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative diseases, today announces they have signed into a Research Collaboration with Annogen, the company behind the SuRE™ technology, for the identification of CNS-cell specific synthetic promoters for use in VectorY’s vectorized antibody programs for neurodegenerative diseases.

Using its proprietary Survey of Regulatory Elements (SuRE™) technology, Annogen functionally annotates the entire human non-coding genome to identify regulatory DNA elements that control therapeutic gene expression for gene & cell therapy. Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner. The SuRE™ technology is unique among other promoter-identification technologies in functionally testing non-coding promoter elements throughout the entire genome including at remote sites where activity is regulated.

“We are delighted to work together with Annogen because novel tailored cell-specific promoters are an important addition to VectorY’s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative diseases such as ALS,” Sander van Deventer CEO of VectorY said.

“VectorY is a leading example of novel advanced approaches to gene therapy development ” Joris van Arensbergen CEO of Annogen adds. “Their focus on controlling various aspects of vector design, including cell-specific promoters, proves the value we can bring with our SuRE™ technology. We are very pleased to work with this forward thinking team and further build our track record in this field.

VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise on antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease. For more information, see www.vectorytx.com.